Tech Company Financing Transactions
Gladius Pharmaceuticals Funding Round
Lumira Capital , Fonds de solidarite FTQ and GlaxoSmithKline participated in a $4.1 million Series A venture round for Gladius Pharmaceuticals. The funding round was recorded on 6/24/2015.
Transaction Overview
Company Name
Announced On
6/24/2015
Transaction Type
Venture Equity
Amount
$4,100,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3575 Avenue du Parc 4310
Montreal QC, H2X 3P9
Canada
Montreal QC, H2X 3P9
Canada
Phone
Website
Email Address
Overview
Gladius Pharmaceuticals Inc. is a Montréal-based biotechnology firm developing novel drugs to treat life-threatening, multi-drug-resistant bacterial infections. Gladius is a disruptive platform technology play, capable of developing multiple novel drug candidates.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Paul Truex
Chief Scientific Officer
Larry Sutton
VP - Finance
Lynda Choquette
Browse more venture capital transactions:
Prev: 6/24/2015: Yotpo venture capital transaction
Next: 6/24/2015: Indix venture capital transaction
Share this article
About Database of VC Transactions
We document all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs